
Cortagen is a synthetic peptide derived from a fragment of the ACTH (adrenocorticotropic hormone) molecule. It is designed to exert neuroprotective and nootropic effects, making it a subject of interest in the field of neurobiology. Cortagen has been studied for its potential to improve cognitive function, support brain health, and protect against neurodegenerative diseases. Its mechanisms are linked to enhancing neuronal survival, reducing inflammation, and promoting brain plasticity.
Most Common Uses
Cortagen is primarily used in certain regions, such as Russia, for its neuroprotective and bioregulatory properties. Medical professionals employ it to support recovery from neurological conditions, including traumatic brain injuries, stroke, and neurodegenerative disorders. The peptide is believed to enhance cognitive function and promote neuronal repair, making it a candidate for treating memory impairments and cognitive decline associated with aging.
In clinical practice, Cortagen is also explored for its potential to improve mental clarity and focus in patients with neurological deficits. It is used in short treatment courses tailored to the patient’s needs. Its application remains limited to specific regions due to varying regulatory approvals, and ongoing research continues to investigate its broader therapeutic potential.
Mechanism of Action
Cortagen exerts its effects primarily through neuroprotective and neuromodulatory mechanisms in the central nervous system. It interacts with neuronal cells to promote repair and regeneration, particularly in the context of neurological damage from conditions like stroke or traumatic brain injury. The peptide enhances synaptic plasticity by modulating neurotransmitter activity, including the regulation of glutamate and gamma-aminobutyric acid (GABA), which supports balanced neuronal signaling.
Cortagen also stimulates the production of neurotrophic factors, fostering neuronal survival and growth. Its anti-inflammatory properties help reduce oxidative stress in brain tissue, creating a favorable environment for recovery. These combined actions contribute to improved cognitive function and neurological restoration, making Cortagen a valuable agent in regions where it is approved for clinical use.
Structure and Pharmacology
Cortagen is a synthetic tetrapeptide with the amino acid sequence H-Ala-Glu-Asp-Pro-OH (one-letter code: AEDP). Its molecular formula is C17H26N4O9, and it has a molecular weight of 430.4 g/mol. The peptide’s compact structure, consisting of alanine, glutamic acid, aspartic acid, and proline, contributes to its stability and ability to interact with neurological pathways. This simple yet specific sequence allows Cortagen to penetrate biological barriers effectively, enabling its therapeutic effects in the central nervous system. The design of Cortagen reflects its role as a bioregulatory peptide, tailored to support neuronal function and repair.
Pharmacologically, Cortagen exerts its effects through neuroprotective and neuromodulatory actions, primarily targeting the central nervous system. Administered via intramuscular or subcutaneous injection, it promotes neuronal repair by stimulating the production of neurotrophic factors, which support neuron survival and growth. The peptide enhances synaptic plasticity by regulating neurotransmitter activity, particularly glutamate and gamma-aminobutyric acid (GABA), fostering balanced neuronal signaling.
Cortagen also exhibits anti-inflammatory properties, reducing oxidative stress in brain tissue, which aids recovery from neurological conditions such as stroke or traumatic brain injury. Its short half-life, typical of small peptides, necessitates daily dosing in clinical settings, with treatment courses often spanning 5 to 10 days. The ability of Cortagen to cross the blood-brain barrier ensures direct interaction with cerebral tissues, supporting its use in improving cognitive function and neurological recovery.
Dosages
Cortagen is typically administered via intramuscular or subcutaneous injection. For adults, the standard dose ranges from 0.1 to 5 milligrams (mg) per day, depending on the neurological condition being treated, such as stroke, traumatic brain injury, or cognitive impairment. Treatment courses generally last up to 20 days, with daily injections, and may be repeated after a break of one to two months based on medical evaluation. In most cases the cycle is repeated 2 to 3 times per year as needed.
Before injection, the lyophilized powder should be dissolved in sterile water or saline, ensuring proper preparation for safe administration. Dosage regimens are tailored to the patient’s needs, with progress monitored to optimize therapeutic outcomes.
Warnings and Cautions
Cortagen requires careful administration to ensure safety. Patients with known allergies to Cortagen or its components should avoid its use, as hypersensitivity reactions, such as rash or swelling, may occur and require immediate medical attention. People with severe liver or kidney dysfunction need close monitoring, as the peptide’s metabolism and clearance may be altered, potentially leading to adverse effects. Pregnant or breastfeeding women should avoid using Cortagen as safety data in these populations are limited. In pediatric patients, where Cortagen is sometimes used for neurological conditions, precise weight-based dosing is necessary to avoid complications. Mild side effects, such as irritation at the injection site, may occur, but persistent or severe symptoms warrant medical evaluation. Patients should be carefully monitored during treatment to rule out any unexpected reactions, ensuring Cortagen is used safely and effectively.
Research & Clinical Trials
Epigenetic Regulation of Aged Heterochromatin by Cortagen
The synthetic peptide Cortagen helps repair and restore the function of damaged peripheral nerves and also makes important changes to how DNA is packed inside cells. Specifically, Cortagen was shown to loosen tightly packed DNA (heterochromatin), turn on ribosomal genes by opening certain chromosome regions, and free up genes that were turned off by reshaping other parts of the DNA structure. Importantly, it did not change the DNA regions that are normally kept tightly packed near the center of chromosomes. These results suggest that Cortagen can reshape DNA organization in aging cells, which may help develop new treatments for age-related diseases. [1]
Cortagen for Brain Disorders in Ischemia
The study concluded that both Cortexin and Cortagen help speed up the recovery of behavioral impairments in rats with brain ischemia, regardless of whether they had high or low resistance to low oxygen (hypoxia). Additionally, the drugs prevented excessive lipid peroxidation (a damaging oxidative process) and preserved antioxidant activity in brain tissue. Overall, the findings suggest that Cortexin and Cortagen may enhance the effectiveness of neuroprotective therapy for chronic brain ischemia. [2]
Cortagen’s Effect on Mouse Heart Gene Expression
This study found that the synthetic peptide Cortagen changes how certain genes in the heart work. Out of more than 15,000 genes studied, Cortagen significantly affected 110 of them, either turning them up or down. Some genes became much more active, while others became less active. When researchers compared Cortagen’s effects to other peptides (Vilon, Epitalon) and the hormone melatonin, they noticed both similarities and unique actions. These results suggest that Cortagen can influence heart health at the genetic level, which may help explain its potential benefits for aging and cardiovascular function. [3]
Sourcing
USA
- LIMITLESS LIFE NOOTROPICS aka Biotech
-
Use Discount Code: EP20
Copied EP20
- SCANTIFIX
-
Use Discount Code: Exploringpeptides
Copied Exploringpeptides
Canada
Europe
- DNLABResearch
-
Use Discount Code: EP15
Copied EP15
Australia
- LVLUPHEALTH
-
Use Discount Code: Exploringpeptides
Copied Exploringpeptides
- SCANTIFIX
-
Use Discount Code: Exploringpeptides
Copied Exploringpeptides
References
[1] Lezhava, T., Monaselidze, J., Jokhadze, T. et al. Epigenetic Regulation of “Aged” Heterochromatin by Peptide Bioregulator Cortagen. Int J Pept Res Ther 21, 157–163 (2015). https://doi.org/10.1007/s10989-014-9443-7
[2] Zarubina, I. V., & Shabanov, P. D. (2011). Eksperimental'naia i klinicheskaia farmakologiia, 74(2), 8–15.
[3] Anisimov, S. V., Khavinson, V. K.h, & Anisimov, V. N. (2004). Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray. Neuro endocrinology letters, 25(1-2), 87–93.


